CYP2A6 and breast carcinoma: In a clinical trial comparing letrozole to exemestane treatment in women with breast cancer, plasma letrozole concentrations were significantly associated with CYP2A6 genotype, such that patients with reduce-of-function genetic variants exhibited higher letrozole concentrations compared to wild-type (CYP2A6*1/*1) patients [148].